295 related articles for article (PubMed ID: 11896446)
1. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R
Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors.
Rochlitz CF; Jantscheff P; Bongartz G; Dietrich PY; Quiquerez AL; Schatz C; Mehtali M; Courtney M; Tartour E; Dorval T; Fridman WH; Herrmann R
Adv Exp Med Biol; 1998; 451():531-7. PubMed ID: 10026923
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells.
Jantscheff P; Herrmann R; Spagnoli G; Reuter J; Mehtali M; Courtney M; Rochlitz C
Cancer Immunol Immunother; 1999 Sep; 48(6):321-30. PubMed ID: 10473807
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors.
Rochlitz C; Jantscheff P; Bongartz G; Dietrich PY; Quiquerez AL; Schatz C; Mehtali M; Courtney M; Tartour E; Dorval T; Fridman WH; Herrmann R
Cancer Gene Ther; 1999; 6(3):271-81. PubMed ID: 10359213
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM
Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492
[TBL] [Abstract][Full Text] [Related]
9. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.
Dummer R; Rochlitz C; Velu T; Acres B; Limacher JM; Bleuzen P; Lacoste G; Slos P; Romero P; Urosevic M
Mol Ther; 2008 May; 16(5):985-94. PubMed ID: 18388930
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.
Tartour E; Mehtali M; Sastre-Garau X; Joyeux I; Mathiot C; Pleau JM; Squiban P; Rochlitz C; Courtney M; Jantscheff P; Herrmann R; Pouillart P; Fridman WH; Dorval T
Br J Cancer; 2000 Dec; 83(11):1454-61. PubMed ID: 11076653
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy.
Heinzerling L; Burg G; Dummer R; Maier T; Oberholzer PA; Schultz J; Elzaouk L; Pavlovic J; Moelling K
Hum Gene Ther; 2005 Jan; 16(1):35-48. PubMed ID: 15703487
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
13. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Duval L; Schmidt H; Kaltoft K; Fode K; Jensen JJ; Sorensen SM; Nishimura MI; von der Maase H
Clin Cancer Res; 2006 Feb; 12(4):1229-36. PubMed ID: 16489078
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
Khorana AA; Rosenblatt JD; Sahasrabudhe DM; Evans T; Ladrigan M; Marquis D; Rosell K; Whiteside T; Phillippe S; Acres B; Slos P; Squiban P; Ross M; Kendra K
Cancer Gene Ther; 2003 Apr; 10(4):251-9. PubMed ID: 12679797
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.
Ray A; Williams MA; Meek SM; Bowen RC; Grossmann KF; Andtbacka RH; Bowles TL; Hyngstrom JR; Leachman SA; Grossman D; Bowen GM; Holmen SL; VanBrocklin MW; Suneja G; Khong HT
Oncotarget; 2016 Sep; 7(39):64390-64399. PubMed ID: 27391442
[TBL] [Abstract][Full Text] [Related]
19. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
20. Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
